NMN and NR Safety in Adults 65 and Older: What the Evidence Actually Shows

Why Geriatric Adults Are Drawn to NAD+ Precursors

Adults over 65 represent the fastest-growing segment of NAD+ precursor consumers, according to supplement industry sales data from 2023 and 2024. The logic is straightforward: NAD+ levels decline with age, and restoring them might slow aspects of biological aging. That reasoning, while biologically plausible, skips over a critical gap in the published evidence.

The foundational preclinical work by Imai and Guarente (2014) established that NAD+ depletion correlates with age-related metabolic dysfunction in mice. Aged mice given NMN showed improved mitochondrial function, better glucose handling, and extended healthspan markers. These findings generated significant enthusiasm in the longevity community.

But mouse physiology is not human physiology. Mice metabolize nicotinamide derivatives faster, have different renal clearance profiles, and do not take metformin, statins, or anticoagulants. The geriatric patient sitting in a clinic chair carries a pharmacological and physiological complexity that no mouse model captures. Before examining what NMN and NR can do for older adults, the more pressing question is what we don't yet know about their safety in this population.

What the Human Trial Data Actually Covers

The most frequently cited NMN trial is Yoshino et al. (2021, Science), which randomized 25 postmenopausal prediabetic women to NMN 250 mg/day or placebo for 10 weeks. The study found improved skeletal muscle insulin sensitivity and increased NAD+ metabolites in plasma. The mean participant age was 58 years. No participant was 65 or older.

That trial lasted 10 weeks. It enrolled 25 people. It measured metabolic endpoints, not safety outcomes in the geriatric sense (falls, cognitive changes, renal biomarkers, or medication interactions).

A 2022 study by Yi et al. gave healthy middle-aged adults NMN at doses up to 1,250 mg/day for 60 days and reported no serious adverse events. Mild GI symptoms appeared in roughly 12% of the NMN group versus 8% in placebo. Again, the cohort skewed younger than 65.

For NR, the evidence base is slightly broader. Martens et al. (2018) conducted a crossover trial of NR 500 mg twice daily (1,000 mg/day) in 24 healthy middle-aged and older adults for 6 weeks. Mean age was 65, making this the closest any published trial has come to a true geriatric cohort. Blood NAD+ rose by approximately 60%. Blood pressure dropped by a mean of 2-4 mmHg in participants with baseline prehypertension. No serious adverse events were reported.

The Endocrine Society has not issued specific guidance on NAD+ precursor supplementation in older adults. The American Geriatrics Society Beers Criteria does not list NMN or NR, largely because these compounds have not been evaluated through the regulatory processes that would bring them to the Beers panel's attention.

Renal Clearance: The Geriatric Concern That No Trial Has Addressed

This is the safety issue that should concern clinicians most. Both NMN and NR are metabolized through the NAD+ salvage pathway, producing nicotinamide as an intermediate. Nicotinamide is then methylated in the liver to N-methyl-nicotinamide (MeNAM), which is further oxidized to 2-pyridone-5-carboxamide (2-PY) and 4-pyridone-3-carboxamide (4-PY). All three metabolites are eliminated by the kidneys.

Age-related decline in glomerular filtration rate (GFR) is near-universal. The Baltimore Longitudinal Study of Aging demonstrated that GFR decreases by approximately 0.75 mL/min/year after age 40 in the absence of overt kidney disease. By age 75, many adults have a GFR between 45 and 60 mL/min, placing them in CKD stage 3a even without a diagnosis of chronic kidney disease.

High-dose niacin (nicotinic acid), a related NAD+ precursor, is known to cause hyperuricemia and can worsen renal function in patients with pre-existing kidney disease. The AIM-HIGH trial found that extended-release niacin at 1,500-2,000 mg/day was associated with a small but statistically significant rise in serum creatinine over 3 years. NMN and NR generate the same downstream metabolites as niacin, though through a different upstream pathway and typically at lower doses.

No published study has measured 2-PY or 4-PY accumulation in adults over 65 taking NMN or NR. No study has tracked serum creatinine or cystatin C prospectively in geriatric NMN or NR users. This is not evidence of harm. It is an absence of evidence in the population most vulnerable to harm from impaired metabolite clearance.

A reasonable clinical approach: any adult over 65 considering NMN or NR should have a baseline metabolic panel including eGFR. If eGFR is below 45 mL/min, the risk-benefit calculus shifts considerably, and supplementation should be discussed with a physician who can monitor renal biomarkers at 4- to 8-week intervals.

Drug Interactions in Polypharmacy Patients

The average American aged 65-69 takes four prescription medications. By age 80, that number rises to seven. NMN and NR enter a crowded metabolic environment in the typical geriatric patient, and the interaction data is essentially nonexistent.

The theoretical concerns are grounded in known biochemistry. NAD+ is a cofactor for sirtuins (SIRT1-7) and poly(ADP-ribose) polymerases (PARPs). Raising NAD+ levels alters the activity of these enzymes, which in turn influence drug metabolism pathways. Cantó et al. (2012) showed that NR activates SIRT1 and SIRT3, which modulate mitochondrial function and could theoretically affect the metabolism of drugs processed through mitochondrial pathways.

Specific interactions to consider:

Metformin. Both metformin and NAD+ precursors affect AMPK signaling. The MILES trial (Kulkarni et al., 2018) found that metformin alters the NAD+ metabolome in older adults. Whether co-administration with NMN or NR produces additive, synergistic, or antagonistic effects on glucose metabolism is unknown.

Warfarin and direct oral anticoagulants. Niacin at pharmacological doses has been associated with modest INR elevation in warfarin users. Whether NMN or NR at supplement-grade doses produce the same effect has not been tested. Given the catastrophic consequences of supratherapeutic anticoagulation in a 78-year-old with fall risk, this gap matters.

Statins. High-dose niacin combined with statins increases myopathy risk, as documented in the FDA safety communication on niacin-statin combinations. NMN and NR produce nicotinamide rather than nicotinic acid, and the myopathy risk appears to be specific to nicotinic acid. Theoretical risk remains low, but zero clinical data confirm this assumption in geriatric statin users.

Antihypertensives. The Martens et al. trial showed NR reduced systolic blood pressure by 2-4 mmHg. For an older adult on amlodipine and lisinopril with a baseline systolic of 118, that additional reduction could produce symptomatic hypotension, dizziness, and falls. Orthostatic hypotension already affects 15-30% of community-dwelling adults over 65.

Hepatic Metabolism and the Aging Liver

The liver is the primary site of NAD+ biosynthesis and nicotinamide metabolism. Hepatic blood flow decreases by 35-40% between ages 25 and 65, according to data from the Wynne et al. study (1989). Phase I drug metabolism capacity, mediated by cytochrome P450 enzymes, declines in parallel.

NMN is converted to NAD+ via nicotinamide mononucleotide adenylyltransferase (NMNAT), an enzyme expressed in the liver, brain, and other tissues. NR follows a slightly different path, first being converted to NMN by nicotinamide riboside kinases (NRK1 and NRK2) before entering the same NMNAT step.

Whether these enzymatic conversion steps become rate-limiting in an aging liver with reduced blood flow is unknown. A 2024 review in Ageing Research Reviews noted that "the pharmacokinetics of NAD+ precursors in adults over 70 represent a critical knowledge gap that must be filled before dosing recommendations can be made for this population."

The practical concern: if hepatic conversion of NMN to NAD+ slows with age, more unmetabolized NMN or nicotinamide may circulate, increasing the burden on renal excretion. This creates a compounding problem in the geriatric patient who already has reduced GFR.

GI Tolerability and Nutritional Concerns

Gastrointestinal side effects are the most commonly reported adverse events across NMN and NR trials. Nausea, abdominal discomfort, bloating, and loose stools occur in 10-15% of participants at doses above 500 mg/day.

For a 72-year-old with gastroparesis from longstanding type 2 diabetes, or an 80-year-old already taking six medications that each carry their own GI burden, adding a supplement that causes nausea in one out of eight users is not trivial. Poor oral intake in older adults compounds sarcopenia, weakens immune function, and increases fall risk.

Nicotinamide at high doses can deplete methyl donors (S-adenosylmethionine, folate, betaine) because its hepatic clearance requires methylation. The Minto et al. (2017) review highlighted that chronic high-dose nicotinamide supplementation could theoretically exacerbate hyperhomocysteinemia, a condition already more prevalent in older adults due to declining B12 and folate absorption. No clinical trial has measured homocysteine levels in geriatric NMN or NR users, but the biochemical logic is sound enough to warrant monitoring in patients with known B12 deficiency or elevated baseline homocysteine.

What a Responsible Monitoring Protocol Looks Like

Given the evidence gaps, any clinician supervising NMN or NR use in a patient 65 or older should consider a structured monitoring approach.

Before starting supplementation: Obtain a comprehensive metabolic panel (including eGFR), complete blood count, homocysteine, uric acid, and liver function tests. Document the full medication list, including over-the-counter supplements and herbals. Record orthostatic blood pressure measurements (supine and standing at 1 and 3 minutes).

Dosing considerations: Start at 250 mg/day for NMN or 300 mg/day for NR. Hold at the starting dose for at least 4 weeks before any increase. Maximum studied doses (1,250 mg NMN, 1,000 mg NR) were tested in younger cohorts and should not be assumed safe in adults with eGFR <60 or hepatic impairment.

At 4 weeks: Repeat metabolic panel, liver function tests, and uric acid. Check orthostatic vitals. Ask specifically about nausea, diarrhea, flushing, and any change in bruising or bleeding (particularly relevant for patients on anticoagulants).

At 12 weeks and ongoing: If no adverse signals appear, extend monitoring intervals to every 3 months. Continue tracking eGFR. Any decline of more than 5 mL/min from baseline warrants dose reduction or discontinuation.

Deprescribing lens: Before adding NMN or NR, consider whether the patient's existing supplement and medication burden could be simplified. The 2023 update to the AGS Beers Criteria emphasizes that adding supplements without reviewing the full medication list increases adverse event risk in older adults.

The Gap Between Marketing and Medicine

NAD+ precursor manufacturers market heavily to older adults, using language about "reversing aging" and "restoring youthful energy." The biological premise is real: NAD+ does decline with age, and preclinical data in aged mice are genuinely compelling.

But the distance between "NMN restored NAD+ levels in a 24-month-old mouse" and "NMN is safe and effective for a 78-year-old woman on metformin, amlodipine, and rivaroxaban" is vast. That distance is measured in unfinished clinical trials, unasked pharmacokinetic questions, and unstudied drug interactions.

Dr. Charles Brenner, who first identified NR as an NAD+ precursor and published the foundational work on its metabolism in Cell (2004), has stated: "The hype has outpaced the science. We need proper dose-finding studies in older adults before making broad recommendations."

The responsible position for clinicians is neither blanket prohibition nor uncritical endorsement. NMN and NR are biologically active compounds with plausible mechanisms of benefit and plausible mechanisms of harm in older adults. The safety data simply have not caught up with the consumer demand.

Adults 65 and older who choose to use NMN or NR should do so under medical supervision, with baseline labs, a medication interaction review, and structured follow-up at 4-week and 12-week intervals.